Subscribe To
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA®, Representing YoY Growth of 75% – 80% 2023 FIRDAPSE® Net Revenues Estimated at $245 Million to $255 Million 2023 FYCOMPA Net Revenues Estimated at $130 Million – 11 Months FYCOMPA Business Unit Integration Expected to […] The post Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provide...
Read More
Posted: Feb 7 2023, 13:03
Author Name: forextv
Views: 110655